Rallybio doses first healthy volunteers in Phase 1 study of RLYB116; data expected H2 2022

Rallybio Corp

First healthy volunteers dosed in Phase 1 study of RLYB116.
Single dose safety, PK, and PD data expected in second half of 2022.
Corporate presentation updated to reflect Phase 1 milestone and data timeline.

item 7.01 item 9.01

Rallybio Corp filing history →

Source: SEC EDGAR

accession 0000950170-22-002960

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.